Thrombolytic effect of lonomin V in a rabbit jugular vein thrombosis model

Blood Coagulation and Fibrinolysis

Volumn 12, Issue 7, 2001, Pages 521-529

  Guerrero, Belsy ^a,b   Arocha Piñango, Carmen Luisa ^a   Pinto, M Alves ^b   Muller C A ^b   San Juan, A Gil ^a   Amorim, S ^b   Perales, J ^b  

^a INSTITUTO VENEZOLANO DE INVESTIGACIONES CIENTÍFICAS   (Venezuela)

^b INSTITUTO OSWALDO CRUZ   (Brazil)

Author keywords

Factor XIII; Fibrinolysis; Lonomia achelous; Thrombolysis; Thrombosis

Indexed keywords

ALTEPLASE; FIBRINOLYTIC AGENT; LONOMIN V; UNCLASSIFIED DRUG; UROKINASE;

ANIMAL MODEL; ARTICLE; BLOOD CLOT LYSIS; BOLUS INJECTION; CONTINUOUS INFUSION; CONTROLLED STUDY; DOSE RESPONSE; DRUG ISOLATION; EXPERIMENTAL MODEL; FEMALE; FIBRINOLYTIC THERAPY; HEMOLYMPH; INSECT; JUGULAR VEIN; MALE; NONHUMAN; PRIORITY JOURNAL; RABBIT; THROMBOSIS; VEIN THROMBOSIS;

ANIMALS; ANTICOAGULANTS; ANTIPLASMIN; ARTHROPOD VENOMS; DISEASE MODELS, ANIMAL; FACTOR XIII; FEMALE; FIBRINOGEN; FIBRINOLYTIC AGENTS; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAVENOUS; JUGULAR VEINS; MALE; PLASMINOGEN; RABBITS; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR; URINARY PLASMINOGEN ACTIVATOR; VENOUS THROMBOSIS;

EID: 0034750206     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001721-200110000-00003     Document Type: Article

References (49)

1. Evaluation of recurrent thrombosis and hypercoagulability
2. Overview of the thrombotic process and its therapy
3. Thrombolysis for acute myocardial infarction
4. Thrombolytic therapy
5. Strategies for the improvement of thrombolytic agents
6. Clinical applications of thrombolytic therapy
7. Thrombolytic therapy in acute myocardial infarction
8. Fibrinolysis: An unfinished agenda
9. Mechanism of action of plasminogen activators
10. Development of novel thrombolytic agents
11. TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction
12. Effective thrombolysis without marked plasminemia after bolus intravenous administration of vampire bat salivary plasminogen activator in rabbits
13. Third-generation thrombolytic drugs
14. Fibrinolytic action on fresh human clots of whole body extracts and two semipurified fractions from Lonomia achelous caterpillar
15. Lonomia achelous caterpillar venom (LACV) selectively inactivates blood clotting factor XIII
16. Degradation of human factor XIII by Lonomin V, a purified fraction of Lonomia achelous caterpillar venom
17. Effect on platelet FXIII and partial characterization of Lonomin V, a proteolytic enzyme from Lonomia achelous caterpillars
18. A proteolytic substances from a saturnidae moth caterpillar. Partial isolation and purification
19. Studies of a fibrinolytic enzyme from the larvae of Lonomia achelous (Cramer) using chromogenic peptide substrates
20. Lonomia genus caterpillar toxins: Biochemical aspects
21. Isolation and complete amino acid sequence of two fibrinolytic proteinases from the toxic Saturnid caterpillar Lonomia achelous
22. The action of Lonomia achelous caterpillar venom on some blood coagulation and fibrinolysis parameters of the rabbit
23. Cleavage of structural proteins during the assembly of the head of bacteriophage T-4
24. Protein measurements with the folin phenol reagent
25. Evaluation of the fibrin plate method for estimating plasminogen activator
26. Guidelines for the use of animals in biomedical research
27. Thrombolysis with extrinsic tissue-type plasminogen activator in rabbits with experimental jugular vein thrombosis
28. Valores normales de hemoglobina, hematocrito, factores de coagulación y fibrinolisis en conejos Nueva Zelanda blancos
29. The determination of plasma fibrinogen by clot weight method
30. Plasminogen assay in rabbit, rat and mouse plasma using the chromogenic substrate S-2251
31. A rapid, simple sensitive method for measuring fibrinolytic split products in human serum
32. The preparation and some properties of fibrinogen precipitated from human plasma by glycine
33. Recent advances in cardiology
34. Bolus thrombolysis in venous thromboembolism
35. High-dose bolus injection of urokinase. Use during cardiopulmonary resuscitation for massive pulmonary embolism
36. Thrombolysis and reocclusion in experimental jugular vein and coronary artery thrombosis
37. Thrombolysis for acute stroke
38. Intracranial hemorrhage complicating acute myocardial infarction in the era of thrombolytic therapy
39. A comparison of the thrombolytic and hemorrhagic effects of tissue-type plasminogen activator and streptokinase in rabbits
40. Synergistic effect on thrombolysis of sequential infusion of tissue-type plasminogen activator (t-PA), single-chain urokinase type plasminogen activator (scu-PA) and urokinase in the rabbit jugular vein thrombosis model
41. Fibrin specific thrombolysis by two-chain urokinase-type plasminogen activator cleaved after arginine-156 by thrombin
42. Thrombolytic and pharmacokinetic properties of a recombinant chimeric plasminogen activator consisting of a fibrin fragment D-Dimer specific humanized monoclonal antibody and a truncated single chain urokinase
43. Thrombolytic therapy
44. Cerebral hemorrhagic complications of thrombolytic therapy
45. Coronary arterial thrombolysis with low-dose synergistic combinations of recombinant tissue-type plasminogen activator (rt-PA) and recombinant single-chain urokinase-type plasminogen activator (rscu-PA) for acute myocardial infarction
46. The contribution of activated Factor XIII to fibrinolysis resistance in experimental pulmonary embolism
47. Factor XIII Va134Leu is a genetic factor involved in the aetiology of venous thrombosis
48. Inhibition of F XIIIa in a canine model of coronary thrombosis: Effect on reperfusion and acute reocclusion after recombinant tissue-type plasminogen activator
49. Enhancement of thrombolysis and inhibition of thrombus growth by Lonomin V